LSX World Congress USA 2024
As they plan their assets’ development and launch, pre-commercial biotech companies must navigate a new environment in which funding is harder to obtain. In the past two years, the investment community’s appetite for risk has diminished, and funders have become more selective.
In today’s softened market, pre-commercial companies cannot risk developing assets only to find that they cannot attract the necessary funding for commercialization. Syneos Health is the concierge emerging companies need to help reduce risk, manage costs, optimize performance — and attract funding— in this market.
Meet with Us
Our team of experts will be on the floor at LSX World Congress USA to show how we can help you accelerate your path to full market potential. Schedule a meeting to discuss your specific challenges.
Featured Sessions
Strategies for Maximizing Asset Value Throughout Drug Development
September 11 | 4:15pm ET
Lee Taurman
Executive Vice President, Head of Commercial Strategy and Solutions, Syneos Health
PANEL: What is Required to Scale? Fast-Tracking Biotech Growth to Achieve Global Reach
September 12 | 11am ET
MODERATOR: Vik Chawla
Managing Director, Portfolio Strategy & Transactions, Syneos Health
Related Content:
Want to learn more? Explore Insights Hub for our latest perspectives, subscribe to our podcast, or click the resources below:
Driving Commercial Success with Predictive Analytics and Agile Resourcing
FT Live | De-Risking Investment to Deliver Innovation
FT Live | The Marriage of Biotech Innovators and Big Pharma: Bringing New Drugs to Market
Syneos Health Podcast | Investing for Commercial Success as an Emerging Company
